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SINCE INITIAL EXPERIMENTAL REPORTS by
Harris and Kokernot' and Mosey and Tyler2 diphenylhydantoin (DPH) has been shown to be an effective agent in abolishing various experimental and clinical cardiac arrhythmias in a variety of situations including digitalis toxicity and acute myocardial infarction.3" However, the mechanism of the antiarrhythmic action of DPH has given rise to considerable controversy. Most investigators agree that the drug depresses spontaneous diastolic depolarization and is effective in arrhythmias due to enhanced automaticity.12 14 , " The controversy centers on the effects of DPH on electrophysiologic parameters such as membrane responsiveness and conduction velocity in cardiac cells, which can be major determinants in the establishment conduction in the adjacent normal zone. Prior to abolition of RVA initiated by premature beats (PBs), DPH resulted in: 1) narrowing of the critical range of coupling intervals of PBs that resulted in re-entry (i.e., the re-entry zone), 2) shift of the narrowed re-entry zone to longer cardiac cycle lengths, and 3) lengthening of the coupling interval of the first re-entrant beat, as well as slowing the rate of reentrant tachycardia. Thus DPH, similar to lidocaine, owes its antiarrhythmic action in RVA to its selective depressant effect on ischemic cells forming part of the RP.
or abolition of re-entrant arrhythmias. Bigger et al. ' 2 and Strauss et al. '6 found that DPH in therapeutic concentrations did not decrease membrane responsiveness or conduction velocity. On the contrary, it actually increased these two parameters in addition to abbreviation of both the action potential duration and effective refractory period especially in depressed cardiac cells. The efficacy of DPH in abolishing re-entrant rhythms was thus attributed to improvement of conduction in the re-entrant pathway. '2' 13, 17-19 On the other hand, other investigators have found that DPH effects on cardiac cells are not dissimilar to those of quinidine, 2' producing marked retardation of conduction velocity and depression of membrane responsiveness particularly in the presence of higher extracellular levels of potassium.'5 [21] [22] [23] These findings would suggest that DPH, similar to quinidine, may interrupt re-entrant cycles by conversion of a one-way block into a two-way block."
We have recently analyzed the mechanism of action of lidocaine in re-entrant ventricular arrhythmias in dogs [3] [4] [5] [6] [7] days post myocardial infarction24 utilizing a remarkably stable canine model in which direct recordings of the elec-trical activity of the re-entrant pathway(s) were obtained. [25] [26] [27] Lidocaine in a therapeutic dose was found to "selectively" prolong refractoriness and depress conduction in re-entrant pathways in ischemic myocardium while having no effect on conduction in adjacent normal zone. 24 Depression and/or block of conduction in the re-entrant pathway was the mechanism by which lidocaine abolished re-entrant ventricular arrhythmias. The electrophysiologic effects of lidocaine were reported to be remarkably similar to DPH. '5 18,19 Further, prior to our recent study, the main controversial arguments relating to the mechanism of action of DPH in re-entrant arrhythmias equally applied to lidocaine. 5 ' 18, 19, 23, 24 Therefore, this study was conducted to test the theory that DPH, similar to lidocaine, acts by selective depression of conduction in the re-entrant pathway.
Material and Methods
The results included in this study were obtained from 15 adult mongrel dogs that were studied [3] [4] [5] [6] [7] Panels E to G in figure 1 were obtained following intravenous injection of 10 mg/kg of DPH. Panel E shows that a cycle length of 500 msec was associated with slight widening of the IZ potential compared to control recording in panel A but a 1:1 conduction pattern was still maintained. Shortening the cardiac cycle length to 370 msec in panel IZeg-1 Analysis of figure I shows that DPH resulted in lengthening of refractoriness in areas of the IZ represented by the IZ potential. This would explain the occurrence of rate-related higher degree of conduction block (Wenckebach-like conduction periodicity and 2:1 block of the IZ potential) at relatively long cardiac cycle lengths. However, the conduction disorder induced by DPH was still tachycardiadependent since conduction improved at relatively slow heart rates. On the other hand, analysis of figure 1 shows that DPH had no effect on the NZeg or the QRS configuration and duration in the surface lead. This emphasizes the selective depressant effect of DPH on conduction in the IZ. Figure 2 summarizes the effects of DPH on conduction of the IZ potential in 10 Figure 4 was obtained immediately following the injection of 10 mg/kg of DPH. Compared to control recordings in figure 3 , DPH resulted in the following significant changes: 1) Premature beats with relatively long coupling interval (340 and 330 msec in panels B and C, respectively) produced marked fractionation and delay of the IZ potential resulting in manifest re-entry. The amplitude of the fractionated IZ potential associated with re-entry was significantly lower compared to control recordings in figure 3 , panels C and D.
2) The range of coupling intervals of premature beats that resulted in re-entry (the re-entry zone) was markedly abbreviated compared to control (10 msec compared to 50 msec in fig. 3 ). Panel D shows that although a premature beat with a coupling interval of 320 msec was still associated with some fractionation of the IZ potential it did not result in manifest re-entry. In panel E, a premature beat with a coupling interval of 300 msec resulted in loss of inscription of a major part of the IZ potential reflecting the occurrence of conduction block at a proximal site in the re-entrant pathway. Further shortening of the coupling interval in panels F and G was still associated with conduction block in the re-entrant pathway and no re-entry.
3) The coupling interval NZeg -j--,, - of the first re-entrant beat that reflects the re-entrant pathway conduction time was significantly prolonged compared to the control (from 250-285 msec before DPH to 350-380 msec following DPH). The effects of DPH on re-entry initiated by premature beats in 10 different experiments are summarized in table 1. DPH resulted in obliter-ation of the re-entry zone in five experiments. In three of these experiments recordings obtained immediately following the injection of the drug showed initial narrowing of the re-entry zone before obliteration (figs. [3] [4] [5] . The re-entry zone was narrowed in two other experiments but was not completely obliterated, was lengthened in two and unchanged in one. In the five experiments in which narrowing of the re-entry zone was demonstrated, the coupling intervals of premature beats that still resulted in re-entry were relatively long compared to control ( figs. 3 and 4) . Also, the coupling intervals of the first re-entrant beat were longer following DPH compared to control. In one experiment (#8) premature beats initiated a regular re-entrant ventricular tachycardia at a rate of 280/min. DPH resulted in narrowing of the re-entrant zone and the rate of the re-entrant tachycardia that could still be induced after DPH was relatively slow at 210/min.
In the experiment shown in figures 3-5 only one re-entrant pathway was probably operative judging from the constant QRS configuration of manifest re-entrant beats. However, because the composite IZeg averaged the recordings from multiple sites in the IZ,25 slight or major variations in the reentrant pathway cannot be excluded although the terminal part of the re-entrant pathway probably did not vary significantly. In other experiments, however, the re-entry zone encompassed several potentially re-entrant pathways as revealed by the different QRS configurations of re-entrant beats, as well as varying patterns of the fractionated IZ potential. DPH resulted in abolition of one or all of these reentrant pathways as reflected by failure to initiate certain reentrant beats with a particular QRS configuration. Extensive epicardial mapping could possibly have resulted in better understanding of the effect of DPH on the different potentially re-entrant pathways in the IZ.
The effect of DPH was studied in three other experiments that showed re-entrant beats with regular extrasystolic grouping (one bigeminal rhythm and two trigeminal rhythms), and in two instances of regular re-entrant ventricular tachycardia. Similar to what was described in more detail in the report on lidocaine,'4 DPH resulted in lengthening of the coupling interval of extrasystolic beats before abolition of manifest re-entry. DPH also resulted in slowing of the rate of ventricular tachycardia before its termination.
Discussion
The present study clearly shows that DPH in a dose of 5-10 mg/kg, which is similar to those shown to be associated with clinical therapeutic blood levels" consistently prolonged refractoriness of potentially re-entrant pathways in the IZ. This resulted in further impairment of conduction in the re-entrant pathway and was directly responsible for the ability of DPH to abolish manifest reentrant arrhythmias. Similar to lidocaine,24 there was evidence that DPH gradually slowed conduction in the reentrant pathway prior to the abolition of manifest re-entry which was characteristically associated with complete block in the re-entrant pathway. On the other hand, DPH in the dose utilized had no significant effect on refractoriness or conduction in the closely bordering NZ. Thus, both DPH and lidocaine24 were found to exert their antiarrhythmic action on ischemic re-entrant ventricular arrhythmias by "selectively" prolonging refractoriness of different segments of the re-entrant pathway resulting in further impairment of the already slow re-entrant wave front to the point of complete block. This action is essentially similar, though not identical, to that of quinidine. The difference lies in the greater degree of selectivity of both DPH and lidocaine which in contrast to quinidine does not depress normal cardiac cells at concentrations associated with a therapeutic antiarrhythmic action.
In the study on lidocaine'4 we have illustrated in some detail the mechanism by which the drug abolishes manifest re-entrant beats with extrasystolic grouping as well as its action on re-entrant ventricular tachycardias. Details of DPH action on these two arrhythmias are essentially the same. On the other hand, we have demonstrated in the present study the effect of DPH on re-entry initiated by premature beats. We found that prior to abolition of re-entry initiated by premature beats, DPH resulted in the following characteristic changes: 1) narrowing of the re-entry zone, 2) shift of the narrowed re-entry zone to longer cardiac cycle lengths, 3) lengthening of the coupling of the first re-entrant beat as well as slowing the rate of re-entrant tachycardia. All three changes could be interpreted as evidence that DPH has resulted in prolongation of refractoriness of different segments of the re-entrant pathway. The abolition of reentry which occurred shortly afterwards is explained by further prolongation of refractoriness resulting in consistent block of conduction of premature beats.
Lidocaine was found to have a more consistent effect in abolishing re-entry initiated by premature beats compared to DPH.24 This may be interpreted as evidence that lidocaine exerts a more effective antiarrhythmic action on ischemic reentrant ventricular arrhythmias relative to DPH at comparable therapeutic concentrations. This may also be in line with the clinical impression about their comparative efficacy in the setting of acute or subacute myocardial infarction arrhythmias."0' 13 However, comparison of the clinical efficacy of antiarrhythmic agents in general and especially those with essentially similar mechanisms of action is fraught with difficulties. This is partly related to such factors as: 1) subtle variations between one animal experiment and the other, as well as between different clinical cases; 2) differences in the dose-related responses of various drugs and the relationship between the therapeutic and toxic concentrations; 3) differences in drug sequestration by serum proteins, as well as the rate of delivery to arrhythmogenic zones in the heart; 4) modifying action of ancillary effects of the drug such as their influence on the autonomic nervous system.
Our In the study on lidocaine21 we cautioned against the possibility that a drug that owes its antiarrhythmic properties to the further impairment of the already slow conduction in a re-entrant pathway may have the potential to create successful re-entrant circuits by critically slowing conduction in moderately depressed cells. The finding in the present study that DPH lengthened the re-entry zone in two experiments may be interpreted as evidence that the drug by virtue of its depressant properties resulted in the recruitment of new potentially re-entrant pathways with or without being successful in blocking the original re-entrant circuits. However, it would be expected that the potential of both DPH and lidocaine to create new potential pathways at a therapeutic concentration is far less compared to quinidine or procainamide with their less selective depressant properties.
The results of the present study on DPH, together with the recent study on lidocaine,24 help to clarify in a substantial way the controversy that shrouded the mechanism of action of both drugs on re-entrant arrhythmias for a long time. These studies also establish the concept that an antiarrhythmic agent can act by selective depression of abnormal cardiac cells forming parts of the re-entrant pathway at a concentration that has no effect or even a mild enhancing effect on electrophysiologic properties of normal cardiac cells. Our results point clearly to the potential pitfall of a long practice in basic as well as clinical studies on the actions of antiarrhythmic agents where data obtained from normal cardiac tissues were extrapolated to the pathologic situation. Thus, there is currently no basis to substantiate the concept that both DPH and lidocaine can abolish re-entrant rhythms by improving conduction in the re-entrant pathway,12 13, 17-19 based on the fact that these drugs were shown to occasionally enhance the electrophysiologic properties of normal cardiac cells.'2 16 29-31 This concept was previously doubted by those investigators who showed that both DPH and lidocaine.can have quinidine-like depressant properties on cardiac cells in the presence of a higher potassium concentration. '5' 21-23, 32 However, these studies fall short of emphasizing the fundamental difference in the action of DPH and lidocaine in pathologic versus normal cardiac cells.
The ionic mechanisms for the selective depressant effect of lidocaine and DPH in ischemic cells and potassiumdepolarized cells are still largely conjectural. Our preliminary in vitro studies suggest that ischemia may result in depression of the fast Na channel and that lidocaine and possibly DPH may act by further impairment of this channel.24 Our observations should provide an impetus for further studies not only in terms of the different ionic conductance changes produced by antiarrhythmic drugs in normal and pathologic cardiac cells but also of the nature of these ionic abnormalities in pathologic situations such as acute, subacute or chronic ischemia.
